CYTR - CytRx up 127% on positive arimoclomol data in rare muscle disorder February, 11 2020 10:48 AM CytRx Corporation CytRx (OTC:CYTR +127.1%) announces positive results from a 24-subject Phase 2 pilot study evaluating arimoclomol in patients with a rare progressive muscle disorder called sporadic inclusion body myositis characterized by inflammation, weakness and atrophy.More news on: CytRx Corporation, Healthcare stocks news, Stocks on the move, Read more ...